Circulating Tumor Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Region and Competition, 2020-2030F

Description

Global circulating tumor cells (CTCs) market was valued at USD 6.96 billion in 2024 and is projected to reach USD 10.63 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.52% during the forecast period. The market is experiencing substantial growth, fueled by increasing demand for early cancer detection, the expanding adoption of personalized medicine, and significant advancements in liquid biopsy technologies.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.96 Billion
Market Size 2030	USD 10.63 Billion
CAGR 2025-2030	7.52%
Fastest Growing Segment	Kits & Reagents
Largest Market	North America

Circulating tumor cells-cancerous cells that detach from primary tumors and enter the bloodstream-serve as crucial biomarkers for assessing cancer progression and the risk of metastasis. The ability to detect and analyze CTCs has reshaped cancer diagnostics and treatment monitoring, positioning these technologies as central tools in the evolving landscape of oncology.

Key Market Drivers

Expansion of the Global Healthcare Industry

The expansion of the global healthcare industry is playing a pivotal role in propelling the CTCs market forward. In response to the growing global cancer burden, institutions like the World Health Organization (WHO) have introduced initiatives such as the Guide to Cancer Early Diagnosis, which promotes timely detection and improved access to cancer care.

Healthcare systems are increasingly embracing precision medicine and early detection strategies to improve patient outcomes and reduce long-term treatment costs. CTCs offer a non-invasive and dynamic approach to cancer diagnostics by enabling the real-time tracking of tumor evolution, therapeutic response, and metastatic spread. Their ability to reveal the molecular characteristics of tumors makes them indispensable tools for guiding targeted therapy development and implementation.

The global rise in cancer prevalence further intensifies the need for efficient diagnostic tools. CTC-based technologies provide actionable insights that support the development of individualized treatment plans, making them a key component in the global push toward more precise and effective cancer care.

Key Market Challenges

High Costs Associated with CTC-Based Technologies

Despite their clinical benefits, CTC-based diagnostic technologies face challenges related to high implementation costs. Isolating and identifying circulating tumor cells-present in extremely low concentrations in the bloodstream-requires advanced equipment, including microfluidic devices, high-resolution imaging platforms, and sensitive molecular analysis tools. These systems are not only expensive to develop but also to deploy and maintain, making widespread clinical adoption difficult, particularly in cost-sensitive or resource-constrained healthcare environments. Beyond the cost of testing, substantial research and development (R&D) investments are needed to improve sensitivity, accuracy, and scalability of these technologies.

Key Market Trends

Rising Adoption of Non-Invasive Diagnostic Solutions

An increasing shift toward non-invasive diagnostics represents a significant trend shaping the global CTCs market. As healthcare providers and patients seek safer, faster, and more convenient alternatives to traditional biopsies, liquid biopsy solutions based on CTC detection are gaining momentum.

Liquid biopsy, enabled by a simple blood draw, allows for repeated, real-time monitoring of tumor dynamics without the discomfort or risks associated with tissue biopsies. This has led to the development and approval of tests such as the CellSearch Circulating Tumor Cell (CTC) Test, which is FDA-approved for assessing prognosis in patients with metastatic breast, prostate, or colorectal cancers. A low CTC count is associated with a more favorable outlook, while a high count may signal disease progression.

As this technology matures, liquid biopsy is becoming a cornerstone of precision oncology, offering dynamic insights into treatment effectiveness, disease progression, and early recurrence-all without disrupting patient comfort. This trend is fundamentally transforming how cancer is diagnosed and managed, driving the demand for innovative, non-invasive CTC-based diagnostics across global markets.

Key Market Players

QIAGEN N.V.
Bio-Techne Corp.
Precision Medicine Group, LLC
Bio-Rad Laboratories, Inc.
Natera, Inc.
Illumina, Inc.
Greiner Bio-One International GmbH
Ikonisys Inc.
Creative Bioarray
Abnova Corporation

Report Scope

In this report, the Global Circulating Tumor Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Circulating Tumor Cells Market, By Product:

Kits & Reagents
Blood Collection Tubes
Devices or Systems

Circulating Tumor Cells Market, By Technology:

CTC Detection & Enrichment Methods
CTC Direct Detection Methods
CTC Analysis

Circulating Tumor Cells Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Circulating Tumor Cells Market.

Available Customizations:

Global Circulating Tumor Cells Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Circulating Tumor Cells Market

5. Global Circulating Tumor Cells Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Kits & Reagents, Blood Collection Tubes, Devices or Systems)
- 5.2.2. By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Circulating Tumor Cells Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Technology
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Circulating Tumor Cells Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Technology
- 6.3.2. Mexico Circulating Tumor Cells Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Technology
- 6.3.3. Canada Circulating Tumor Cells Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Technology

7. Europe Circulating Tumor Cells Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Technology
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Circulating Tumor Cells Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Technology
- 7.3.2. Germany Circulating Tumor Cells Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Technology
- 7.3.3. United Kingdom Circulating Tumor Cells Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Technology
- 7.3.4. Italy Circulating Tumor Cells Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Technology
- 7.3.5. Spain Circulating Tumor Cells Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Technology

8. Asia Pacific Circulating Tumor Cells Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Technology
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Circulating Tumor Cells Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Technology
- 8.3.2. India Circulating Tumor Cells Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Technology
- 8.3.3. South Korea Circulating Tumor Cells Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Technology
- 8.3.4. Japan Circulating Tumor Cells Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Technology
- 8.3.5. Australia Circulating Tumor Cells Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Technology

9. South America Circulating Tumor Cells Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Technology
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Circulating Tumor Cells Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Technology
- 9.3.2. Argentina Circulating Tumor Cells Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Technology
- 9.3.3. Colombia Circulating Tumor Cells Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Technology

10. Middle East and Africa Circulating Tumor Cells Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Technology
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Circulating Tumor Cells Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Technology
- 10.3.2. Saudi Arabia Circulating Tumor Cells Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Technology
- 10.3.3. UAE Circulating Tumor Cells Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Technology

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Circulating Tumor Cells Market: SWOT Analysis

14. Porters Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. QIAGEN N.V.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
15.2. Bio-Techne Corp.
15.3. Precision Medicine Group, LLC
15.4. Bio-Rad Laboratories, Inc.
15.5. Natera, Inc.
15.6. Illumina, Inc.
15.7. Greiner Bio-One International GmbH
15.8. Ikonisys Inc.
15.9. Creative Bioarray
15.10. Abnova Corporation